

### Additional file 3

**Table S3. Baseline clinical characteristics of HBeAg-positive CHB patients who received telbivudine treatment in longitudinal cohort.**

| Group                              | CR               | NCR              |
|------------------------------------|------------------|------------------|
| Number                             | 5                | 10               |
| Gender (male/female)               | 2/3              | 7/3              |
| Age (years) *                      | 26 (24-35)       | 25.5 (21-42)     |
| ALT (IU/L) *                       | 142 (55-244)     | 82 (45-649)      |
| HBV DNA (log <sub>10</sub> IU/L) * | 7.96 (6.24-8.88) | 8.72 (6.84-9.02) |
| HBeAg/anti-HBe                     | 5/0              | 10/0             |

\*Data are shown as median (range); ALT, alanine aminotransferase; anti-HBe, antibody to hepatitis B e antigen; CR, complete response; NA, not available; NCR, non-complete response. Fig. 5, available data from 5 CR and 10 NCR.